Mergers & Acquisitions ·
iSpecimen stockholders approve asset acquisition of Foldlab AI and Nasdaq exemptions
ISPCiSpecimen Inc.
At a special meeting on October 9, 2026, iSpecimen Inc. shareholders approved four proposals by majority vote. The company received approval for an asset acquisition from Foldlab AI Ltd., which involves issuing common stock as partial consideration. Shareholders also authorized the issuance of shares underlying pre-funded warrants and future convertible financing transactions exceeding Nasdaq's 19.99% ownership threshold, satisfying Listing Rule 5635(d). A proposal to approve a reverse stock split ranging from one-for-ten to one-for-one hundred was adjourned until October 30, 2026, pending further solicitation of proxies. The company operates in the healthcare technology sector, providing digital pathology and AI-driven diagnostic solutions.